- കോവിഡ് -19 വീഴ്ച: പിഎംഎസിന് ശേഷം ഇന്ത്യാനിവേഷ് ബ്രോക്കിംഗ് ബിസിനസും നിർത്തലാക്കുന്നു - ഇക്കണോമിക് ടൈംസ്
- കൊറോണ വൈറസിനെക്കുറിച്ച് അവബോധം വളർത്തുന്നതിന് വോഡഫോൺ, ബിഎസ്എൻഎൽ നെറ്റ്വർക്ക് പേരുകൾ മാറ്റുക: റിപ്പോർട്ടുകൾ - ഗാഡ്ജെറ്റുകൾ 360
- ടാറ്റ-മിസ്ട്രി വൈരാഗ്യം തുടരുന്നു, പങ്കിടൽ ഏറ്റവും പുതിയ ഫ്ലാഷ് പോയിന്റ് - ലൈവ്മിന്റ്
- 10 പൊതുമേഖലാ ബാങ്കുകളുടെ മെഗാ ലയനം പ്രാബല്യത്തിൽ വരും: അറിയേണ്ട കാര്യങ്ങൾ - ടൈംസ് ഓഫ് ഇന്ത്യ
- ഇയോൺ മോർഗൻ പറയുന്നത് ഇംഗ്ലണ്ട് കളിക്കാർ 'സാധ്യമായ വിധത്തിൽ സഹായിക്കാൻ തയ്യാറാണ്' | ESPNcricinfo.com - ESPNcricinfo
DALLAS, Feb. 25, 2020 — Wearing a removable, adhesive patch sensor accurately predicted worsening heart failure and the need for hospitalization several days before heart failure hospitalization occurred among veterans with heart failure, according to research published today in the American Heart Association’s journal Circulation: Heart Failure.
The participants in the LINK-HF multi-center study consisted of one hundred heart failure (HF) patients who were veterans, average age of 68 years, enrolled at four Veterans Affairs (VA) hospitals — in Salt Lake City; Palo Alto, Calif.; Houston, and Gainesville, Fla. — after an initial acute heart failure admission to the hospital. The participants wore an adhesive sensor patch on their chest 24 hours a day for a minimum of 30 days and up to three months after their initial hospital discharge for a heart failure event. Of the eligible participants, 90% continued to wear the sensor at 30 days, and at 90 days; data was collected from August 2015 through December 2016.
The sensor monitored heart rate, heart rhythm, respiratory rate and physical activities such as, walking, sleeping and body posture for each participant. The data was transmitted from the sensor via Bluetooth to a smartphone, and then uploaded from the smartphone to an analytics platform on a secure computer server. A machine learning algorithm, a type of artificial intelligence approach to data analysis, established a normal baseline for each patient and then examined the incoming data. When observed data deviated from the expected ‘normal baseline’ behavior, the algorithm generated an alert to indicate the patient’s heart failure was getting worse. The technology accurately predicted hospitalization risk more than 80% of the time. This prediction of hospitalization took place an average of 6.5 days before the readmission.
“With the use of remote data from the sensor and through data analysis by machine learning, we have shown that we can predict the future. Next, we will look at whether we can change the future,” said lead study author Josef Stehlik, M.D., M.P.H., the Christi T. Smith Professor of Medicine at the University of Utah School of Medicine, medical director of the Heart Transplant Program and co-chief of the Advance Heart Failure Program at the University of Utah Hospital and the Salt Lake City Veterans Affairs Medical Center.
Heart failure (HF) is a major public health issue – it impacts about 6.2 million U.S. adults and is the No. 1 hospital discharge diagnosis in the U.S. Heart failure-related health care costs were an estimated $30.7 billion in 2012 and are expected to reach $53 billion by 2030. About 80% of these costs are for hospitalization according to a study cited by the researchers and published in 2011. In the first 90 days after discharge from the hospital for heart failure, patients are at a high, up to 30%, risk of readmission. Given this significantly increased risk of HF worsening after hospitalization, the researchers focused on testing a non-invasive solution to improve HF management during this critical time period.
“In chronic heart failure, a person’s condition can get worse with shortness of breath, fatigue and fluid buildup, to the point many end up in the emergency room and spend days in the hospital to recover,” said Stehlik. “If we can identify patients before heart failure worsens and if doctors have the opportunity to change therapy based on this novel prediction, we could avoid or reduce hospitalizations, improve patients’ lives and greatly reduce health care costs. With the evolution of technology and with artificial intelligence statistical methods, we have new tools to make this happen.”
Study limitations included:
- Study participants were 98% male, so it is unknown if these findings would be consistent in females;
- A majority of the participants had HFrEF (heart failure with reduced ejection fraction), so further study in patients with HFpEF (heart failure with preserved ejection fraction) is needed; and
- Additional research is necessary to determine if treatment changes based on the alerts could lead to improved patient outcomes.
In a future study, the researchers will test changing patient treatment based on the alert generated by the algorithm. “We are hoping that with this information, we can intervene and decrease the hospitalization rate, improve quality of life, and, for patients who end up being admitted to the hospital, shorten the length of stay,” concluded Stehlik.
Co-authors are Carsten Schmalfuss, M.D.; Biykem Bozkurt, M.D., Ph.D.; Jose Nativi-Nicolau, M.D.; Peter Wohlfahrt, M.D., Ph.D.; Stephan Wegerich, M.S.; Kevin Rose, B.S.; Ranjan Ray, M.D., Ph.D.; Richard Schofield, M.D., FACC; Anita Deswal, M.D., M.P.H.; Jadranka Sekaric, Ph.D.; Sebastian Anand Ph.D.; Dylan Richards, B.S.; Heather Hanson, R.N.; Matthew Pipke, B.A., J.D.; and Michael Pham, M.D. Disclosures are in the manuscript.
The study was conducted by VA investigators with support and funding from the U.S. Department of Veterans Affairs Office of Information & Technology and the VHA Innovation Ecosystem, in partnership with PhysIQ, Inc.
Available multimedia is on right column of release link – https:/
Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations and health insurance providers are available at https:/
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.